EXEL Exelixis, Inc.

21.32
+0  (1%)
Previous Close 21.04
Open 21.13
Price To book 68.31
Market Cap 6.20B
Shares 290,866,000
Volume 2,064,072
Short Ratio 3.14
Av. Daily Volume 4,570,950

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 planned.
CABOMETYX (cabozantinib) with Opdivo (nivolumab)
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 initiated September 2016.
CS-3150
Essential hypertension
Phase 2 top-line data released May 2016. Presentation of detailed data released at ESMO 2016 Congress, October 10, 2016. sNDA filing due 3Q 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
Phase 3 initiated Sept 2013. Data due 2017.
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer